Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that bind to the 3’untranslated region of target mRNAs and lead to translation repression or mRNA degradation, thus regulating important cell processes. MiRNA deregulation has been identified in virtually all types of cancer, and miRNA profiling has proved useful in cancer diagnosis, prognosis and response to therapy. So far, limited but important evidence of miRNA impaired expression has been reported in multiple myeloma (MM), suggesting implications in the pathogenesis and biology of the disease. In this review, we present a general overview of the role of miRNAs in B-cell development and associated malignancies, focusing on those most extensively characterized. We fully describe seminal studies on miRNA expression in MM, highlighting the correlations of their deregulation with pathogenesis and with distinct molecular subgroups, as well as their role in prognostic stratification. The data obtained in MM, supported by the consolidated role of miRNAs in cancer and their potential effectiveness in therapy, all provide a solid rationale for the more accurate characterization of their deregulation and the development of effective means of selectively delivering miRNAs and anti-miRNAs to myeloma cells in therapeutic approaches.
Keywords: Chromosomal abnormalities, gene expression profiling, microRNAs, multiple myeloma, prognostic stratification, therapeutic target identification, v-akt murine thymoma viral oncogene homolog 1, runt-related transcription factor 1, Cyclin D1/2/3, Cyclic AMP responsive element binding protein 1, DiGeorge syndrome critical region gene 8, Fibroblast growth factor receptor 3, Interferon regulatory factor 4, Mitogen activated protein kinase.
Current Cancer Drug Targets
Title:MicroRNAs in the Pathobiology of Multiple Myeloma
Volume: 12 Issue: 7
Author(s): Marta Lionetti, Luca Agnelli, Luigia Lombardi, Pierfrancesco Tassone and Antonino Neri
Affiliation:
Keywords: Chromosomal abnormalities, gene expression profiling, microRNAs, multiple myeloma, prognostic stratification, therapeutic target identification, v-akt murine thymoma viral oncogene homolog 1, runt-related transcription factor 1, Cyclin D1/2/3, Cyclic AMP responsive element binding protein 1, DiGeorge syndrome critical region gene 8, Fibroblast growth factor receptor 3, Interferon regulatory factor 4, Mitogen activated protein kinase.
Abstract: MicroRNAs (miRNAs) are small non-coding RNAs that bind to the 3’untranslated region of target mRNAs and lead to translation repression or mRNA degradation, thus regulating important cell processes. MiRNA deregulation has been identified in virtually all types of cancer, and miRNA profiling has proved useful in cancer diagnosis, prognosis and response to therapy. So far, limited but important evidence of miRNA impaired expression has been reported in multiple myeloma (MM), suggesting implications in the pathogenesis and biology of the disease. In this review, we present a general overview of the role of miRNAs in B-cell development and associated malignancies, focusing on those most extensively characterized. We fully describe seminal studies on miRNA expression in MM, highlighting the correlations of their deregulation with pathogenesis and with distinct molecular subgroups, as well as their role in prognostic stratification. The data obtained in MM, supported by the consolidated role of miRNAs in cancer and their potential effectiveness in therapy, all provide a solid rationale for the more accurate characterization of their deregulation and the development of effective means of selectively delivering miRNAs and anti-miRNAs to myeloma cells in therapeutic approaches.
Export Options
About this article
Cite this article as:
Lionetti Marta, Agnelli Luca, Lombardi Luigia, Tassone Pierfrancesco and Neri Antonino, MicroRNAs in the Pathobiology of Multiple Myeloma, Current Cancer Drug Targets 2012; 12 (7) . https://dx.doi.org/10.2174/156800912802429274
DOI https://dx.doi.org/10.2174/156800912802429274 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure and Function of the Epstein-Barr Virus Transcription Factor, EBNA 3C
Current Protein & Peptide Science Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets α2-Adrenoceptors Enhance Cell Proliferation and Mammary Tumor Growth Acting Through both the Stroma and the Tumor Cells
Current Cancer Drug Targets LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Opioid Regulation of Mu Receptor Internalisation: Relevance to the Development of Tolerance and Dependence
CNS & Neurological Disorders - Drug Targets Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
Current Pharmaceutical Design RNAi of cat-2, a Putative Tyrosine Hydroxylase, Increases Alpha Synuclein Aggregation and Associated Effects in Transgenic C. elegans
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Physiology and Pathophysiology of Na+/H+ Exchange Isoform 1 in the Central Nervous System
Current Neurovascular Research Pharmacological Roles of the Large-Conductance Calcium-Activated Potassium Channel
Current Topics in Medicinal Chemistry The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology
Current Neuropharmacology Functional Biomarkers: an Approach to Bridge Pharmacokinetics and Pharmacodynamics in Pediatric Clinical Trials
Current Pharmaceutical Design Growth Inhibition of Various Human Cancer Cell Lines by Imperatorin and Limonin from Poncirus Trifoliata Rafin. Seeds
Anti-Cancer Agents in Medicinal Chemistry Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Somatostatin and its Analogs
Current Drug Targets Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology